Report cover image

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 180 Pages
SKU # APRC20355178

Description

Summary

According to APO Research, The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, projected growth trends, production technology, application and end-user industry.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Company

Allergan
Amneal Pharms
Astellas Pharmaceuticals
Bausch Health
Sebela Pharmaceuticals
Pharscin Pharma
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type

XIFAXAN
Lotronex
Viberzi
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application

Hospitals Pharmacy
Retail Pharmacy
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

180 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Manufacturers
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2020-2025)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers, Product Type & Application
3.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Tier 1, Tier 2, and Tier 3
4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Type Introduction
4.1.1 XIFAXAN
4.1.2 Lotronex
4.1.3 Viberzi
4.1.4 Other
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2031)
4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2020-2031)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type
4.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2031)
4.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2020-2031)
5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Application Introduction
5.1.1 Hospitals Pharmacy
5.1.2 Retail Pharmacy
5.1.3 Other
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application
5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020-2031)
5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2020-2031)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
5.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020-2031)
5.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2020-2031)
6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2020-2031)
6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2020-2025)
6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
7.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2020-2025)
7.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2026-2031)
7.1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2020-2031)
7.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2020-2031)
7.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Allergan
8.1.1 Allergan Comapny Information
8.1.2 Allergan Business Overview
8.1.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.1.5 Allergan Recent Developments
8.2 Amneal Pharms
8.2.1 Amneal Pharms Comapny Information
8.2.2 Amneal Pharms Business Overview
8.2.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.2.5 Amneal Pharms Recent Developments
8.3 Astellas Pharmaceuticals
8.3.1 Astellas Pharmaceuticals Comapny Information
8.3.2 Astellas Pharmaceuticals Business Overview
8.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.3.5 Astellas Pharmaceuticals Recent Developments
8.4 Bausch Health
8.4.1 Bausch Health Comapny Information
8.4.2 Bausch Health Business Overview
8.4.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.4.5 Bausch Health Recent Developments
8.5 Sebela Pharmaceuticals
8.5.1 Sebela Pharmaceuticals Comapny Information
8.5.2 Sebela Pharmaceuticals Business Overview
8.5.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.5.5 Sebela Pharmaceuticals Recent Developments
8.6 Pharscin Pharma
8.6.1 Pharscin Pharma Comapny Information
8.6.2 Pharscin Pharma Business Overview
8.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
8.6.5 Pharscin Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis
9.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
9.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
9.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.